Page 203 - Drug Class Review

Drug Effectiveness Review Project

Groups similar at baseline: Yes
Alzheimer classification: Mild

donepezil placebo 75.1 73.3 60 50 NR NR 2.5 2.9 24.3 24.1 Primary Outcome Measures: Change from baseline to end point on the modified ADAS-cog total score Secondary Outcome Measures: Change from baseline on the MMSE; CDR-Sum of Boxes; CMBT; Timing of assessments: Screening, baseline, every 6 weeks Health Outcome Measures: Significant improvement over placebo was observed in the donepezil group at endpoint on the modified ADAS-cog total score (difference 2.3 points); P = 0.001 Intermediate Outcome Measures: Significant improvem

Apathy Scale • • •

Final Report Update 1 Authors: Seltzer et al. Year: 2004 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: Onset cognitive symptoms • (yrs) MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs